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Introduction
A low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet is predominantly used to reduce symptoms in patients with irritable bowel syndrome (IBS) and is now commonly used worldwide. With increasing use, comes increasing sources of information, including the Internet, books, smartphone apps, and advice from health professionals including general practitioners, gastroenterologists, dietitians, and alternative health practitioners. Patients will often turn to lay information that unfortunately usually only provides estimations about FODMAP content of food. This poses problems with proper diagnosis of IBS and appropriate application of the diet. Manipulation of FODMAPs is best done in conjunction with a dietitian, not only well versed in the low FODMAP diet but also well versed in IBS. Some of the services provided by a dietitian include assessment of the patient and appropriate dietary treatment, explanation of the pathophysiology of IBS, explanation of the recommended treatment, and ways to individualize the treatment to the patient.
Applying a low FODMAP diet. There are two main strategies that a dietitian may take in applying a FODMAP restriction: the top-down or the bottom-up approach, as described in Table 1 . The top-down approach usually involves the over-restriction of FODMAPs for a 4-week to 8-week period, whereby the patient will closely restrict all or most foods that contain FODMAPs above the arbitrary level set by Monash University. Then, if symptomatic benefit is seen, dietary liberalization is guided by using set food and dose "challenges" or via general recommendations describing FODMAP dosing across restricted foods. In contrast, the bottom-up approach describes the reduction of a few foods that are very high in FODMAPs or reduction of a few targeted FODMAPs for a time period then further restriction of foods only if necessary.
Irritable bowel syndrome phenotypes. Irritable bowel syndrome is a heterogeneous condition, with a complex pathophysiology. There are many possible abnormalities in the bowel function of patients with IBS. This current review will discuss four main features: visceral hypersensitivity, enhanced gut-brain communication, altered motility, and altered microbiome. Patients with IBS may have alterations in one or a combination of these features, and it may be difficult at times to distinguish the abnormality.
Visceral hypersensitivity. Abdominal pain is a typical symptom seen in patients with visceral hypersensitivity, but other symptoms of IBS are commonly also present. Theoretically, a low FODMAP diet is best targeted to this group of patients as its mechanism of action is to reduce luminal distension and associated symptoms. [1] [2] [3] Barostat studies have shown that visceral hypersensitivity is present in up to 65% of IBS patients. 4 Rates of efficacy of the low FODMAP diet have consistently been around 75% for clinically significant reduction in symptoms. 5 Considering there is always an element of placebo in any efficacious treatment, it is likely that the efficacy of the diet corresponds with the rate of hypersensitive patients although this has not yet been formally confirmed. Other treatments targeting reduced sensation or visceral stimulation are composed of antispasmodic agents including peppermint oil, simethicone, mebeverine hydrochloride, and butylscopolamine, which have small benefit over placebo (58% vs 46%). 6 These may be considered as adjunct therapy to a low FODMAP diet or an alternative when FODMAP manipulation is less practical to apply (e.g. when eating out). Other dietary therapies targeted for visceral hypersensitivity include the reduction or elimination of bioactive food components, which stimulate specific receptors including naturally occurring food chemicals (salicylates, amines, and glutamate) and food additives (colors, preservatives, and flavor enhancers). Unfortunately, rates of efficacy for a low food chemical diet in IBS patients have never been published, and Australian protocols that have been set to assess food chemical sensitivities involve very restrictive elimination diets, which are often labor intensive and likely to be nutritionally inadequate. This treatment may be contraindicated in patients at risk of malnutrition.
Enhanced gut-brain communication.
Patients who associate symptoms with stress, anxiety, or nervous situations may have enhanced communication of the gut-brain axis. However, enhanced symptom perception is not limited solely to those with conscious stress-related triggers. Both cognitive behavioral therapy and gutdirected hypnotherapy have efficacy in management of IBS with similar outcomes as that seen with a low FODMAP diet. 7 Psychological intervention is dependent on service accessibility and often incurs a large cost and time commitment for the patient. but it does reduce osmotic activity through the large bowel; thus, a FODMAP restriction may be efficacious in patients with fast transit to lessen their diarrhea. It is known that the degree of polymerization is directly and inversely related to osmolarity 8 ; therefore, a reduction in monosaccharides (including polyols) and disaccharides may be enough to reduce symptoms rather than a full low FODMAP diet. A therapy targeted to make stool consistency more formed and subsequently lessen fecal frequency and urgency is the use of the fiber supplement, psyllium. 9 The exceptional viscosity and water-holding capacity of psyllium can be an advantage in symptom management, although its tendency to swell may also promote bloating and abdominal discomfort. Lastly, loperamide, a μ-opioid-receptor agonist, will suppress colonic peristalsis and thereby may reduce diarrhea. 10 However, loperamide does not have an effect on other symptoms associated with IBS including pain.
Patients with slow or uncoordinated colonic transit may present with constipation or possibly with overflow diarrhea. Patients often will describe difficulty passing gas and stool, and they may only be relieved of their symptoms after total bowel clearing. A low FODMAP diet seems not to work well in promoting faster transit but may lessen associated bloating and discomfort commonly seen in the presence of constipation. Often, the first attempt to promote faster transit is laxative therapy, which may include a combination of fiber, fluid, osmotic, and stimulant agents. There is conflicting evidence for the efficacy of a high fiber diet to treat symptoms of IBS, with literature suggesting that fiber types should be considered individually. For example, supplemented soluble fibers including psyllium and linseeds may reduce overall symptoms in IBS and ease stool passage, but effect of insoluble bran fiber may worsen clinical outcomes. 11, 12 Inherently, a low-fiber diet may exacerbate constipation and subsequent symptoms. Particularly in patients who are already reducing their FODMAP intake, fiber, which commonly coexists with FODMAPs, may also be reduced and oppose the benefit of the low FODMAP diet. In general, osmotic laxatives are suitable to try if they are not fermentable. Thus, polyethylene glycol and magnesium sulfate (Epsom salts) may be used to improve stool frequency, whereas prune juice or lactulose are more likely to be poorly tolerated. Stimulating agents works well to relieve symptoms, although short-term or intermittent use of senna and bisacodyl is usually 13 inclusion of caffeinated beverages, and regular exercise, in particular, running, which promotes increased motility, through mechanical factors and neuro-immuno-endocrine secretions.
14 Lastly, considerations of pelvic floor dysfunction, which may respond to bowel retraining or the implementation of adequate toileting positioning and practices, are of particular importance in patients with symptoms of evacuatory dysfunction or fear of public or communal toilets.
Altered microbiome. Altered gut microbiota has been argued to be involved in the pathogenesis of symptoms in all patients with IBS; however, the normal composition of the gut microbiome is yet to be determined, limiting potential therapeutic interventions. Specific populations with clear changes in microbiota include patients with post-infectious IBS 15 and possibly patients with small intestinal bacterial overgrowth. An untested hypothesis is that long-term application of a low FODMAP diet, which is known to negatively alter total and specific beneficial bacterial species, 16 may in turn lead to or worsen IBS severity. This is one reason to liberalize FODMAP restriction to the minimum level needed for individual symptom control. Diet aside, there is evidence that treatments targeted to correcting bacterial balance may be helpful in patients with IBS. Specific antibiotic, namely, Rifaximin, has some efficacy in IBS 17 but can be costly and difficult to access in some countries. There is weak evidence for the use of probiotics to lessen IBS symptoms, with the exception of Bifidobacterium infantis 35624 showing small clinical benefit. 18 Prebiotics may have merit in positively altering the microbiome and subsequent IBS symptoms, but they are also FODMAPs, which may exacerbate symptoms. Indeed, one study that provided oligosaccharides to patients with IBS showed that symptoms initially increased, although ongoing use resulted in symptom adaption. 19 Non-irritable bowel syndrome conditions. The nonspecific symptoms seen in IBS can be identical to that seen in organic disease, and a lack of IBS biomarkers that may be used as a diagnostic test is likely to increase risk of misdiagnosis. Careful consideration must be taken for organic disease that would seemingly fit into the IBS diagnosis. Patient assessment of alarming features (e.g. nocturnal symptoms, unexpected weight loss, and older age at symptom onset) is essential to indicate appropriate investigations. Response to diet is a poor predictor of IBS and should not be considered in patient assessment, particularly, as many other conditions that mimic IBS are influenced by diet such as coeliac disease, bile salt malabsorption, and pancreatic insufficiency. Furthermore, abdominal symptoms that do not fit into the diagnosis of IBS should also be considered, such as acute fecal loading, non-coeliac gluten sensitivity, anorectal muscular impairment, and an altered expectation of what is considered "normal."
Expectation of normal. Interest in diet for prevention of disease is growing amongst the community. Additionally, therapeutic diets are more commonly used than ever before and are sometimes self-prescribed. With dietary therapies becoming more common, misuse and misunderstanding of their role as treatment is widespread. Some patients have unrealistic expectations of what diet can offer and even altered perception of what is considered a symptom (e.g. considering normal bowel variation constipation or diarrhea), and there is a common misconception that food is a cause, rather than a treatment for IBS. An exaggeration of this is orthorexia, a condition in which the patient avoids specific foods in the belief that they are harmful. Patients with orthorexia will always attribute symptoms to food; despite IBS being influenced by multiple factors, they will often overanalyze food and symptoms and sometimes present with extended self-initiated food and symptom diaries. Patients with orthorexia are more likely to never break their diet and will often limit social situations that are based around food. Thorough explanation of the pathophysiology of IBS and the role of diet and non-diet treatments will often separate the illinformed patients from the patients with orthorexia. Clarification of what is considered a normal symptom that is experienced in the asymptomatic healthy population and, if the patient has IBS, discussion about what is considered a realistic reduction in symptoms with various treatments is also of benefit. Patients with orthorexia would usually benefit from application of a non-dietary treatment to draw attention away from food. Psychological assessment and intervention is advised.
Conclusion
The complexity of IBS and the variety of treatments need methodical consideration and personalization. A low FODMAP diet has excellent rates of efficacy in treating IBS, but unfortunately, there are no clear predictors of response. In the event of poor response to a low FODMAP diet, other dietary, psychological, and pharmacological treatments must be considered. The role of a dietitian in IBS management is necessary to properly assess and educate the patient with IBS and will aid in appropriate delivery of dietary therapy while ensuring nutritional and psychological health.
